Axonics (MEX:AXNX) Total Liabilities : MXN1,468 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Axonics Total Liabilities?

Axonics's Total Liabilities for the quarter that ended in Mar. 2024 was MXN1,468 Mil.

Axonics's quarterly Total Liabilities increased from Sep. 2023 (MXN873.16 Mil) to Dec. 2023 (MXN1,397.98 Mil) and increased from Dec. 2023 (MXN1,397.98 Mil) to Mar. 2024 (MXN1,468.14 Mil).

Axonics's annual Total Liabilities increased from Dec. 2021 (MXN1,343.81 Mil) to Dec. 2022 (MXN1,739.32 Mil) but then declined from Dec. 2022 (MXN1,739.32 Mil) to Dec. 2023 (MXN1,397.98 Mil).

Axonics Total Liabilities Historical Data

The historical data trend for Axonics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Total Liabilities Chart

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

694.41

1,090.80

1,343.81

1,739.32

1,397.98

Axonics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,605.76	830.73	873.16	1,397.98	1,468.14

Axonics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Axonics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	777.692	+	(438.615	+	-5.6843418860808E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	181.675	+	0)
	=	1,398

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	12220.152	-	10822.169
	=	1,398

Axonics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	803.043	+	(500.443	+	0.00099999999991951
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	164.651	+	0)
	=	1,468

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	11875.633	-	10407.495
	=	1,468

Axonics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Axonics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (MEX:AXNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (MEX:AXNX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AXNX:USA

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.